Denali Therapeutics (DNLI) EBIT (2017 - 2024)
Historic EBIT for Denali Therapeutics (DNLI) over the last 8 years, with Q4 2024 value amounting to -$129.8 million.
- Denali Therapeutics' EBIT rose 205.62% to -$129.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$487.3 million, marking a year-over-year decrease of 14775.98%. This contributed to the annual value of -$487.3 million for FY2024, which is 14775.98% down from last year.
- According to the latest figures from Q4 2024, Denali Therapeutics' EBIT is -$129.8 million, which was up 205.62% from -$123.2 million recorded in Q3 2024.
- In the past 5 years, Denali Therapeutics' EBIT ranged from a high of $244.1 million in Q4 2020 and a low of -$132.6 million during Q4 2023
- For the 5-year period, Denali Therapeutics' EBIT averaged around -$62.9 million, with its median value being -$81.4 million (2021).
- Its EBIT has fluctuated over the past 5 years, first surged by 52258.73% in 2020, then crashed by 16838.98% in 2024.
- Over the past 5 years, Denali Therapeutics' EBIT (Quarter) stood at $244.1 million in 2020, then tumbled by 131.6% to -$77.1 million in 2021, then crashed by 36.6% to -$105.3 million in 2022, then fell by 25.85% to -$132.6 million in 2023, then increased by 2.06% to -$129.8 million in 2024.
- Its EBIT was -$129.8 million in Q4 2024, compared to -$123.2 million in Q3 2024 and -$116.6 million in Q2 2024.